[Recent development of new drugs for the treatment of allergic diseases].
Due to the prevalence of allergic diseases such as bronchial asthma, allergic rhinoconjunctivitis and dermallergosis, efforts at the discovery of novel and effective medications for prevention and treatment of these conditions have been reinforced. Recently, it has been recognized that these allergic diseases are a chronic inflammatory disorder of the lower and upper airways and skin. In this article, we reviewed the recent development of the following new antiallergic therapies: anti-Th2 cytokine antibodies, decoy receptors, receptor antibodies, anti-IgE antibodies, anti-cell adhesion molecules antibodies, antisense oligonucleotides, keratinocyte modulators, inhibitors of phosphodiesterase 4, tachykinin receptor antagonists, and anti-histaminic drugs. Most of these new agents are aimed to inhibit various components of allergic inflammation. The future use of allergic disease therapies hold great promise and excitement.
Ohmori
Kenji
K
Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Suntogun, Shizuoka, Japan. kenji.ohmori@kyowa.co.jp
Adachi
Kei
K
Manabe
Haruhiko
H
Harada
Daisuke
D
Ohshima
Etsuo
E
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000631:Aminopyridines; D000818:Animals; D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077608:Aprepitant; D001549:Benzamides; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D018925:Chemokines / Q000037:antagonists & inhibitors; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D003521:Cyclopropanes; D016207:Cytokines / Q000037:antagonists & inhibitors; D003713:Dendritic Cells; D015195:Drug Design; D006634:Histamine H1 Antagonists; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy / Q000209:etiology; D007073:Immunoglobulin E / Q000276:immunology; D015603:Keratinocytes; D008407:Mast Cells; D009025:Morpholines; D009490:Neurosecretory Systems; D000069444:Omalizumab; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors; D014498:Uracil / Q000031:analogs & derivatives*
D000631:Aminopyridines; D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001549:Benzamides; D015815:Cell Adhesion Molecules; D018925:Chemokines; D003521:Cyclopropanes; D016207:Cytokines; D006634:Histamine H1 Antagonists; D009025:Morpholines; D018039:Receptors, Tachykinin; C424423:Roflumilast; D000077608:Aprepitant; D000069444:Omalizumab; D007073:Immunoglobulin E; D014498:Uracil; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; C418807:CX 659S